Navigation Links
Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
Date:9/5/2011

AMSTERDAM, September 6, 2011 /PRNewswire/ --


Gains US Patent Protection for Proprietary AAV Intellectual Property

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that it has entered into an exclusive license agreement with the US National Institutes of Health (NIH) for use of adeno-associated virus serotype 5 (AAV5)-based gene therapy vectors for liver and brain indications. This agreement expands on an original non-exclusive license for AAV5 from the NIH. Financial details of the agreement have not been disclosed.

Concurrent with the signing of this exclusive license, AMT has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for its patent application entitled "AAV vectors produced in insect cells", which covers a core asset of the Company's proprietary manufacturing technology. This patent comprises a novel and significantly improved method of delivery of therapeutic genes to targets using adeno-associated viral (AAV) derived vectors produced in insect cells. The technology has already been successfully applied to Glybera®, a gene therapy for lipoprotein lipase deficiency (LPLD). AMT believes this intellectual property together with the NIH exclusive license places the Company in a unique position for a number of AAV serotype 5-based programs, including hemophilia, acute intermittent prophyria, GDNF-related diseases and Sanfilippo B.

"This expansion of our existing AAV5 license with NIH is an important addition to our intellectual property position as it supports several of our pipeline products that follow Glybera. The granting of an exclusive license by the NIH is very unusual and we believe acknowledges AMT's status in the gene therapy sector," stated Jörn Aldag, CEO of AMT. "As well as continuing to work diligently towards the re-examination of Glybera registration dossier, we also appreciate the significant value and need to patients of the other gene therapy programs."

About Amsterdam Molecular Therapeutics

AMT is a world leader in the development of human gene based therapies. The company's lead product Glybera®, a gene therapy for lipoprotein lipase deficiency (LPLD), is currently under review by the European Medicines Agency (EMA). If approved, Glybera will be the first gene therapy product to be marketed in Europe. AMT also has a product pipeline of several gene therapy products in development for hemophilia B, Duchenne muscular dystrophy, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate probably the world's first stable and scalable AAV manufacturing platform. This proprietary platform can be applied to a large number of rare (orphan) diseases caused by one faulty gene and allows AMT to pursue its strategy of focusing on this sector of the industry.  AMT was founded in 1998 and is based in Amsterdam. Further information can be found at http://www.amtbiopharma.com.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of AMT only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business. AMT expressly disclaims any intent or obligation to update any forward-looking statements herein except as required by law. 



'/>"/>
SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
2. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
4. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
7. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
8. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
9. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
10. Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
11. Molecular sleuths track evolution through the ribosome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... ... January 13, 2017 , ... ... demand that it has found among its diverse customer base. The latest entry ... in most brands electroporators including BTX and Bio-Rad. FireflySci is introducing three distinct ...
(Date:1/12/2017)... ... January 12, 2017 , ... ... of performing routine electrochemical biosensing has increased dramatically. Primarily driven by the ... and quantification of various analytes in complex samples. , Screen-printed ...
(Date:1/12/2017)... 2017   Protein Sciences Corporation , a ... Flublok Influenza Vaccine ®, announced today that its ... safety results and induced strong neutralizing antibodies against ... is expected to advance into human clinical trials ... Institute of Technology in Immunobiologicals of the Oswaldo ...
(Date:1/11/2017)... ... January 11, 2017 , ... Phase 1 clinical trial ... of the investigational anti-cancer agent tucatinib (formerly ONT-380) against HER2+ breast cancer. The ... percent of these heavily pretreated patients saw clinical benefit from the drug, with ...
Breaking Biology Technology:
(Date:1/6/2017)... , Jan. 5, 2017  Delta ID Inc., a ... scanning technology for automotive at CES® 2017. Delta ID ... ) to demonstrate the use of iris scanning as ... authenticate the driver in a car, and as a ... driving experience. Delta ID and Gentex will ...
(Date:12/22/2016)... SuperCom (NASDAQ:   SPCB ... Safety, HealthCare, and Finance sectors announced today that Leaders in Community ... and deploy a community-based supportive services program to reduce recidivism in ... expanding its presence in the state. ... This new program, which is expected to commence ...
(Date:12/16/2016)... , Dec 16, 2016 Research and Markets ... Market - Global Forecast to 2021" report to their offering. ... The biometric ... grow at a CAGR of 14.06% from 2016 to 2021. The ... is projected to reach 854.8 Million by 2021. The growth of ...
Breaking Biology News(10 mins):